| ADTX 0.0127 -2.31% | SOXS 4.72 -5.03% | SPCX 160.95 19.22% | DFNS 0.233 -9.20% | BITO 8.65 0.12% | RUBI 0.4676 -24.62% | TZA 4.16 -2.58% | CAST 1.55 140.68% | AAL 14.98 2.25% | INTC 124.57 6.51% | SPCE 3.91 -31.76% | SHFS 0.276 16.46% | SRXH 0.148 17.65% | NOK 14.795 5.00% | NVDA 205.19 0.16% | BYAH 1.47 40.00% | SPDN 8.81 -0.45% | TQQQ 77.52 1.99% | TSLL 13.59 3.58% | PAVS 0.208 -28.28% | CPOP 0.195 -81.43% | SMCI 30.46 -4.72% | CUPR 3.97 64.73% | VSME 1.69 52.25% | YYGH 0.119 -3.25% | SQQQ 40.04 -1.93% | RKLB 102.39 -10.79% | TSLA 406.43 1.82% | NVD 5.02 -0.40% | WOK 0.0753 -17.70% | SPY 741.75 0.54% | ASTS 82.41 -15.53% | KEEL 5.59 1.27% | ONDS 9.33 -5.09% | SPYM 87.06 0.25% | AMZN 238.55 -1.23% | XLF 53.34 1.37% | SATS 114.08 -10.97% | QQQ 721.34 0.59% | SOFI 16.58 -0.54% | PLUG 2.76 -2.47% | SOXL 234.68 4.77% | GRAB 3.3 -1.49% | DRIP 4.74 -2.47% | AMC 2.34 2.63% | IREN 59.77 5.40% | HKIT 0.5025 -10.11% | RKLZ 3.01 21.37% | RZLV 2.68 5.93% | MARA 14.08 3.45%

Surgery Partners, Inc. (NASDAQ: SGRY) Faces Challenges but Shows Potential for Recovery

Surgery Partners, Inc. (NASDAQ: SGRY) is a healthcare services company that operates surgical facilities across the United States. The company provides a range of surgical services, including orthopedics, pain management, and ophthalmology. SGRY competes with other healthcare service providers like Tenet Healthcare and HCA Healthcare.
 
On March 3, 2026, amid the post-earnings reaction, the stock traded around $13.41 during the session. Despite the market reaction, SGRY’s stock price recently hit a 52-week low during a premarket session. This decline followed the release of disappointing fourth-quarter results and a cautious outlook for 2026. The company reported adjusted earnings of 12 cents per share, missing the expected 30 cents. This shortfall contributed to the stock’s decrease of approximately 12.91%, with a change of $2.05, bringing the price to $13.83 at one point during the session. However, not all news was negative for SGRY.
 
The company reported a 2.4% increase in sales year over year, reaching $885 million, which surpassed the consensus estimate of $866.47 million. Same-facility revenues for the fourth quarter of 2025 also saw a 3.5% increase, with revenue per case rising by 2.1% and same-facility cases increasing by 1.3%. These figures indicate some positive operational performance despite the overall challenges. The adjusted EBITDA for the fourth quarter was $156.9 million, down from $163.8 million the previous year. Additionally, cash flows from operating activities decreased to $103.4 million, compared to $111.4 million in the fourth quarter of 2024.
 
CEO Eric Evans acknowledged significant and unanticipated headwinds faced by the company, which contributed to the cautious outlook for 2026. SGRY’s market capitalization is approximately $1.79 billion, with a trading volume of 4,007,837 shares. The stock has fluctuated between a low of $12.25 and a high of $13.83 today, with a 52-week high of $24.64. Despite recent setbacks, the consensus analyst price target suggests potential for recovery and growth in the future.
Published on: March 3, 2026